Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, September 19, 2016

Siponimod May Slow Worsening in SPMS


Click here to receive MS news via e-mail

EXPAND study shows 21% reduction in 3-month confirmed disability progression
September 17, 2016

LONDON -- A novel sphingosine-1-phosphate (S1P) receptor modulator may stall disability progression in patients with secondary progressive MS, researchers reported here.
In the EXPAND study, SPMS patients on siponimod had a 21% reduced risk of 3-month confirmed disability progression compared with those on placebo (HR 0.79, 95% CI 0.65 to 0.95, P=0.013), Ludwig Kappos, MD, of University Hospital Basel in Switzerland, reported during a late-breaking session at the ECTRIMS meeting here.

The drug also hit a number of key secondary endpoints, with the exception of the timed 25-foot walk test (T25FW), which trended in the right direction but wasn't significant, Kappos reported.
As seen in earlier studies, it also didn't carry the cardiac initial dosing effects often occurring with fingolimod (Gilenya), he said.

MS Views and News
Providing educational information, resources and services for those affected by MS

No comments: